Codebreaker Tx, Inc. — SEC Form D Filing
Codebreaker Tx, Inc. filed an SEC Form D on August 26, 2026, reporting $5.88M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 26, 2026
- Amount reported
- $5.88M
- Round stage
- Seed
- Industry
- Biotechnology
- Website
- https://codebreakerlabs.io/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
The vast majority of genomic variants are uninterpretable, meaning the function of genetic variations in the human genome cannot be mapped effectively. This lack of clarity leads to significant delays and uncertainty for patients seeking answers from genetic data.
Solution
Codebreaker Labs is building the world's largest dataset of causal variant effects on human cell behavior using a proprietary synthetic biology platform. This platform programs cells with numerous genomic variants and uses single-cell assays to generate phenotypic fingerprints, creating a continuously expanding Codex of experimentally validated variant profiles to train AI.
Why now
The convergence of advanced synthetic biology, high-throughput single-cell assays, and sophisticated AI/machine learning allows for the generation and interpretation of large-scale, causal genomic data that was previously impossible.
Verdict
Investors backed a technical solution to a foundational problem in genomics, anticipating that early control of a unique causal variant dataset would create significant downstream value. This cleared because of the strong bet on proprietary data generation, not because the immediate commercial path to revenue was clearly defined. Investors implicitly bet on the convergence of synthetic biology and AI creating a data moats in an area where correlative data was abundant but causal data scarce, limiting upside to the pace and cost-efficiency of data generation before larger players could replicate or acquire similar capabilities.
Source: SEC EDGAR Form D filing